» Articles » PMID: 34802073

The Applicability of Established Clinical and Histopathological Risk Factors for Tumor Recurrence During Long-term Postoperative Care in Meningioma Patients

Abstract

Risk factors to predict late-onset tumor recurrence in meningioma patients are urgently needed to schedule control intervals during long-term follow-up. We therefore analyzed the value of established risk factors for postoperative meningioma recurrence for the prediction of long-term prognosis. Correlations of clinical and histopathological variables with tumor relapse after 3, 5, and 10 years following microsurgery were analyzed in uni- and multivariate analyses, and compared to findings in the entire cohort. In the entire cohort (N = 1218), skull base location (HR: 1.51, 95%CI 1.05-2.16; p = .026), Simpson ≥ IV resections (HR: 2.41, 95%CI 1.52-3.84; p < .001), high-grade histology (HR: 3.70, 95%CI 2.50-5.47; p < .001), and male gender (HR: 1.46, 95%CI 1.01-2.11; p = .042) were independent risk factors for recurrence. Skull base location (HR: 1.92, 95%CI 1.17-3.17; p = .010 and HR: 2.02, 95%CI 1.04-3.95; p = .038) and high-grade histology (HR: 1.87, 95%CI 1.04-3.38; p = .038 and HR: 2.29, 95%CI 1.07-4.01; p = .034) but not subtotal resection (HR: 1.53, 95%CI .68-3.45; p = .303 and HR: 1.75, 95%CI .52-5.96; p = .369) remained correlated with recurrence after a recurrence-free follow-up of ≥ 3 and ≥ 5 years, respectively. Postoperative tumor volume was related with recurrence in general (p < .001) but not beyond a follow-up of ≥ 3 years (p > .05). In 147 patients with a follow-up of ≥ 10 years, ten recurrences occurred and were not correlated with any of the analyzed variables. Skull base tumor location and high-grade histology but not the extent of resection should be considered when scheduling the long-term follow-up after meningioma surgery. Recurrences ≥ 10 years after surgery are rare, and predictors are lacking.

Citing Articles

Topographic Patterns of Intracranial Meningioma Recurrences-Systematic Review with Clinical Implication.

Corvino S, Altieri R, La Rocca G, Piazza A, Corazzelli G, Palmiero C Cancers (Basel). 2024; 16(12).

PMID: 38927972 PMC: 11201517. DOI: 10.3390/cancers16122267.


Meningioma recurrence: Time for an online prediction tool?.

Albakr A, Baghdadi A, Karmur B, Lama S, Sutherland G Surg Neurol Int. 2024; 15:155.

PMID: 38840600 PMC: 11152515. DOI: 10.25259/SNI_43_2024.


Radiomics-Based Prediction of TERT Promotor Mutations in Intracranial High-Grade Meningiomas.

Akkurt B, Spille D, Peetz-Dienhart S, Kiolbassa N, Mawrin C, Musigmann M Cancers (Basel). 2023; 15(17).

PMID: 37686690 PMC: 10486806. DOI: 10.3390/cancers15174415.

References
1.
Birzu C, Peyre M, Sahm F . Molecular alterations in meningioma: prognostic and therapeutic perspectives. Curr Opin Oncol. 2020; 32(6):613-622. DOI: 10.1097/CCO.0000000000000687. View

2.
Brokinkel B, Hinrichs F, Schipmann S, Grauer O, Sporns P, Adeli A . Predicting postoperative seizure development in meningiomas - Analyses of clinical, histological and radiological risk factors. Clin Neurol Neurosurg. 2020; 200:106315. DOI: 10.1016/j.clineuro.2020.106315. View

3.
Brokinkel B, Spille D, Brokinkel C, Hess K, Paulus W, Bormann E . The Simpson grading: defining the optimal threshold for gross total resection in meningioma surgery. Neurosurg Rev. 2020; 44(3):1713-1720. PMC: 8397672. DOI: 10.1007/s10143-020-01369-1. View

4.
Goldbrunner R, Minniti G, Preusser M, Jenkinson M, Sallabanda K, Houdart E . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9):e383-91. DOI: 10.1016/S1470-2045(16)30321-7. View

5.
Meissner A, Gutsche R, Galldiks N, Kocher M, Junger S, Eich M . Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases. Neuro Oncol. 2021; 24(8):1331-1340. PMC: 9340614. DOI: 10.1093/neuonc/noab294. View